Radiolabelling in 2025: How New Chemistry, Smarter Targeting and Digital Tools Are Changing Nuclear Medicine
Discover how radiolabelling in 2025 is transforming clinical care with advanced technologies and precise therapeutic solutions.
Discover how radiolabelling in 2025 is transforming clinical care with advanced technologies and precise therapeutic solutions.
Yttrium-90 FAPi-46 targets fibroblast activation protein, providing effective radiotherapy for tumours and fibrotic diseases.
Lutetium-177 PSMA-R2 is a urea-based therapeutic agent targeting PSMA, effectively treating advanced prostate cancer patients.
Lutetium-177 LNC1010, a radiolabelled therapy, targets somatostatin receptors, delivering precise treatment with minimal side effects.
Lutetium-177 FAPI-04 revolutionises cancer treatment by precisely targeting cancer-associated fibroblasts, enabling dual imaging and radiotherapy functionalities for enhanced outcomes.
Lutetium-177 DPI-4452 pioneers precision radiotheranostics, revolutionising treatment for CAIX-expressing solid tumours through targeted imaging, therapy, and personalised oncology care advancements.
Advancing cancer diagnostics, the study evaluates Ga-68 FAPi-46 PET imaging’s potential to map FAP expression non-invasively in solid tumours.
Gallium, predicted by Mendeleev, now revolutionises medical diagnostics with its unique radiopharmaceutical applications in oncology.
Gallium-68 DOTATOC revolutionises neuroendocrine tumor diagnosis, enhancing PET imaging accuracy, sensitivity, and management in the medical field.
Gallium-67 citrate is a radiopharmaceutical used for imaging infections, inflammation, cancer, and fever of unknown origin.
Imaging of β-amyloid plaques are necessary for clinical and neuropsychological characteristics in Alzheimer’s disease.